Perfuze Secures FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Comprehensive Stroke Thrombectomy System

Perfuze Receives FDA 510(k) Clearance for NeuroSheath, Completing Its Comprehensive Stroke Thrombectomy System Perfuze, a neurovascular medical device company focused on developing technologies for the treatment of stroke, has announced…

Read MorePerfuze Secures FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Comprehensive Stroke Thrombectomy System

Pattern Bioscience Begins Early Evaluation of Its Pneumonia ID/AST Panel at Five U.S. Clinical Laboratories

Pattern Bioscience Advances Pneumonia ID/AST Panel Evaluation Across Five U.S. Clinical Microbiology Laboratories Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, has announced that its Pneumonia ID/AST…

Read MorePattern Bioscience Begins Early Evaluation of Its Pneumonia ID/AST Panel at Five U.S. Clinical Laboratories

Aphena Pharma Solutions Implements QAD Adaptive ERP, Establishing a Modern Foundation for Enterprise Operations

Aphena Pharma Solutions Goes Live on QAD Adaptive ERP, Modernizing Pharmaceutical Manufacturing and Business Operations Aphena Pharma Solutions, a leading U.S.-based pharmaceutical contract manufacturing and packaging organization, has successfully gone…

Read MoreAphena Pharma Solutions Implements QAD Adaptive ERP, Establishing a Modern Foundation for Enterprise Operations

Povofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Incyte Receives European Commission Approval for Povofortay as a Once-Daily Oral Treatment for Moderate to Severe Hidradenitis Suppurativa Incyte has announced that the European Commission (EC) has approved Povofortay® (povorcitinib)…

Read MorePovofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Gilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement

Gilead Sciences Signs Royalty-Free Licensing Agreements to Support Potential Future Access to Investigational Obeldesivir for Ebola Prevention Gilead Sciences, has announced royalty-free voluntary licensing agreements with three generic pharmaceutical manufacturers…

Read MoreGilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement

Quanterix Broadens Access to Blood-Based Alzheimer’s Testing Through Exclusive Partnership with Sherman Abrams Laboratory in New Jersey and Surrounding Areas

Quanterix Partners with Sherman Abrams Laboratory to Expand Access to LucentAD Complete Alzheimer’s Blood Testing Across New Jersey and Metro New York Quanterix Corporation, a company developing advanced ultrasensitive biomarker…

Read MoreQuanterix Broadens Access to Blood-Based Alzheimer’s Testing Through Exclusive Partnership with Sherman Abrams Laboratory in New Jersey and Surrounding Areas